214 related articles for article (PubMed ID: 16541048)
1. Lyme vaccine demonized by advocacy groups.
McSweegan E
Nature; 2006 Mar; 440(7082):278. PubMed ID: 16541048
[No Abstract] [Full Text] [Related]
2. The need for a new vaccine against lyme borreliosis.
Barrett PN; Portsmouth D
Expert Rev Vaccines; 2013 Feb; 12(2):101-3. PubMed ID: 23414400
[No Abstract] [Full Text] [Related]
3. Arthritis following recombinant outer surface protein A vaccination for Lyme disease.
Rosé CD; Fawcett PT; Gibney KM
J Rheumatol; 2001 Nov; 28(11):2555-7. PubMed ID: 11708435
[TBL] [Abstract][Full Text] [Related]
4. Lyme disease vaccination: safety first.
Stricker RB; Johnson L
Lancet Infect Dis; 2014 Jan; 14(1):12. PubMed ID: 24355028
[No Abstract] [Full Text] [Related]
5. Lyme disease vaccination: are we ready to try again?
Lantos PM
Lancet Infect Dis; 2013 Aug; 13(8):643-4. PubMed ID: 23665340
[No Abstract] [Full Text] [Related]
6. Lyme disease vaccination: safety first - authors' reply.
Barrett PN; Crowe BA; Wressnigg N; Portsmouth D; Aichinger G
Lancet Infect Dis; 2014 Jan; 14(1):12-13. PubMed ID: 24355029
[No Abstract] [Full Text] [Related]
7. Lyme disease: uphill struggle.
Abbott A
Nature; 2006 Feb; 439(7076):524-5. PubMed ID: 16452949
[No Abstract] [Full Text] [Related]
8. Lyme disease vaccination: safety first - author's reply.
Lantos PM
Lancet Infect Dis; 2014 Jan; 14(1):13. PubMed ID: 24355030
[No Abstract] [Full Text] [Related]
9. A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies.
Barrett PN; Portsmouth D
Expert Rev Vaccines; 2013 Sep; 12(9):973-5. PubMed ID: 24053389
[No Abstract] [Full Text] [Related]
10. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
Beran J; De Clercq N; Dieussaert I; Van Hoecke C
Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
[TBL] [Abstract][Full Text] [Related]
11. Need for a New Lyme Disease Vaccine.
Plotkin SA
N Engl J Med; 2016 Sep; 375(10):911-3. PubMed ID: 27602662
[No Abstract] [Full Text] [Related]
12. Into the woods. New weapons against Lyme disease.
Peters S
Adv Nurse Pract; 1999 Oct; 7(10):53-4, 82. PubMed ID: 10808773
[No Abstract] [Full Text] [Related]
13. Availability of Lyme disease vaccine.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Jan; 48(2):35-6, 43. PubMed ID: 9933128
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial.
Wressnigg N; Pöllabauer EM; Aichinger G; Portsmouth D; Löw-Baselli A; Fritsch S; Livey I; Crowe BA; Schwendinger M; Brühl P; Pilz A; Dvorak T; Singer J; Firth C; Luft B; Schmitt B; Zeitlinger M; Müller M; Kollaritsch H; Paulke-Korinek M; Esen M; Kremsner PG; Ehrlich HJ; Barrett PN
Lancet Infect Dis; 2013 Aug; 13(8):680-9. PubMed ID: 23665341
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial.
Sikand VK; Halsey N; Krause PJ; Sood SK; Geller R; Van Hoecke C; Buscarino C; Parenti D;
Pediatrics; 2001 Jul; 108(1):123-8. PubMed ID: 11433064
[TBL] [Abstract][Full Text] [Related]
16. A brief history of OspA vaccines including their impact on diagnostic testing for Lyme disease.
Wormser GP
Diagn Microbiol Infect Dis; 2022 Jan; 102(1):115572. PubMed ID: 34763193
[TBL] [Abstract][Full Text] [Related]
17. Outer surface protein A and arthritis in hamsters.
Parenti DL
Infect Immun; 2000 Dec; 68(12):7212-3. PubMed ID: 11203324
[No Abstract] [Full Text] [Related]
18. Safety, immunogenicity, and efficacy of Borrelia burgdorferi outer surface protein A (OspA) vaccine: A meta-analysis.
Zhao H; Bao FF; Liu A
J Infect Dev Ctries; 2017 Jan; 11(1):1-9. PubMed ID: 28141584
[TBL] [Abstract][Full Text] [Related]
19. Lyme disease.
Hayes E
Clin Evid; 2002 Jun; (7):652-64. PubMed ID: 12230693
[No Abstract] [Full Text] [Related]
20. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.
Schoen RT; Sikand VK; Caldwell MC; Van Hoecke C; Gillet M; Buscarino C; Parenti DL
Clin Ther; 2000 Mar; 22(3):315-25. PubMed ID: 10963286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
